MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides

American Journal of Physiology - Cell Physiology

Volumn 295, Issue 5, 2008, Pages

  Gallagher, Patricia E ^a   Ferrario, Carlos M ^a   Tallant, E Ann ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Angiotensin (1 7), mitogen activated protein kinase; Angiotensin converting enzyme 2; Vascular smooth muscle cells

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OKADAIC ACID; PHOSPHATASE; VANADATE SODIUM;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL LYSATE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME REGULATION; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; FLAVONOIDS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OKADAIC ACID; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; VANADATES;

RATTUS;

EID: 56649122620     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00145.2008     Document Type: Article

References (29)

1. Crackower MA, Sarao ROG, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos A., da Costa JZL, Pei YP, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yogil Y, and Penninger JM. Angiotensin-converting enzme 2 is an essential regulator of heart function. Nature 417: 822-828, 2002.
2. Dales NA, Gould AE, Brown JA, Calderwood EF, Guan B, Minor CA, Gavin JM, Hales P, Kaushik VK, Stewart M, Tummino PJ, Vickers CS, Ocain TD, Patane MA. Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc 124: 11852-11853, 2002.
3. Der Sarkissian S, Grobe JL, Yuan L, Narielwala DR, Walter GA, Katovich MJ, Raizada MK. Cardic overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 51: 712-718, 2008.
4. Diez-Freire C, Vaxquez J, de Adjounian MFC, Yuan L, Silver X, Torres R, Raizada MK. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics 27: 12-19, 2006.
5. Diz DI, Garcia-Espinosa MA, Gegick S, Tommasi EN, Ferrario CM, Tallant EA, Chappell MC, Gallagher PE. Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex senitivity for heart rate control in rats. Exp Physiol 93: 694-700, 2008.
6. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1-E9, 2000.
7. Elased KM, Cunha TS, Marcondes FK, Morris M. Brain angiotensin-converting enzymes: role of angiotensin converting enzyme 2 in processing angiotensin II in mice. Exp Physiol 93: 665-675, 2008.
8. Ferrario CM, Averill DB, Brosnihan KB, Chappell MC, Diz DI, Gallagher PE, Tallant Angiotensin-(1-7) EA. It's contribution to arterial pressure control mechanisms. In: Handbook of Experimental Pharmacology, edited by Unger T and Scholkens B. Heidelberg, Germany, 2004, p. 478-518.
9. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 30: 535-541, 1997.
10. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotenin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 28: 104-108, 1996.
11. Gallagher PE, Chappell MC, Ferrario CM, Tallant EA. Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol Cell Physiol 290: C420-C426, 2006.
12. Gurley SB, Allred A, Thu HL, Griffiths R, Mao L, Philip N, Haystead TA, Donoghue M, Breitbart RE, Acton SL, Rockman HA, Coffman TM. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 116: 2218-2225, 2006.
13. Huentelman MJ, Grobe JL, Vazquez J, Steward JM, Mecca AP, Katovich MJ, Ferrario CM, Raizada MK. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 90.5: 783, 2005.
14. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angiotensin II AT1 receptor regulation of ACE2 and angiotensin-(1-7) in aorta of spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 289: H1013-H1019, 2005.
15. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Up-regulation of angiotensin converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43: 1-7, 2004.
16. Kohara K, Brosnihan KB, Chappell MC, Khosla MC, Ferrario CM. Angiotensin-(1-7). A member of circulating angiotensin peptides. Hypertension 17: 131-138, 1991.
17. Kuman R, Singh VP, Baker KM. Kinase inhibitors for cardiovascular disease. J Mol Cell Cardiol 42: 1-11, 2007.
18. Langeveld B, Van Gilst WH, Gio RA, Zijlstra F, Roks AJ. Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension 45: 138-141, 2005.
19. Lowry OH, Rosebrough MJ, Farr AL, Randall RJ. Protein measurement with the Folin-Phenol reagent. J Biol Chem 193: 265-275, 1951.
20. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292: C82-C97, 2007.
21. Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 33: 207-211, 1999.
22. Tallant EA, Diz DI, Ferrario CM. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension 34: 950-957, 1999.
23. Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 42: 574-579, 2003.
24. Tallant EA, Diz DI, Ferrario CM. State-of-the-Art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension 34: 950-957, 1999.
25. Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotension II. Exp Physiol 90: 449-455, 2005.
26. Trask AJ, Averill DB, Ganten D, Chappell MC, Ferrario CM. Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. Am J Physiol Heart Circ Physiol 292: H3019-H3024, 2007.
27. Turner AJ, Tipnis SR, Guy JL, Rice GI, Hooper NM. ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin- converting enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol 80: 346-353, 2001.
28. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang K, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277: 14838-14843, 2002.
29. Zisman LS, Meixell GE, Bristow MR, Canver CC. Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation 108: 1679-1681, 2003.